Dr. Reddy's Laboratories Limited (RDY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $13.13. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of RDY = $18.43 (+40.4% from the current price, the stock appears undervalued).
Valuation: RDY trades at a trailing Price-to-Earnings (P/E) of 17.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.79.
Financials: revenue is $325.5B, +14.9%/yr average growth. Net income is $56.5B, growing at +38.8%/yr. Net profit margin is 17.4% (healthy). Gross margin is 58.5% (+5.4 pp trend).
Balance sheet: total debt is $46.8B against $333.4B equity (Debt-to-Equity (D/E) ratio 0.14, conservative). Current ratio is 1.92 (strong liquidity). Debt-to-assets is 9.5%. Total assets: $493.0B.
Analyst outlook: 6 / 12 analysts rate RDY as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 95/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 88/100 (Pass), Future 40/100 (Partial), Income 70/100 (Pass).
